ACCESSWIRE

Representing Animals Foundation

Share
Dogs Thrive on Vegan Diets, Demonstrates the Most Comprehensive Study So Far

WINCHESTER, UK / ACCESSWIRE / April 23, 2024 / The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat. The study, published in leading scientific journal PLOS ONE, comprehensively assessed the health of 15 dogs by analysing blood cells and biochemistry, blood nutrient levels, urine, veterinary clinical parameters, and monthly pet owner questionnaires. The dogs were fed solely vegan diets based on pea protein for an entire year - just under one tenth of an average dog lifespan, or around seven human years.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Dr. Linde with 'Rylee'

Overweight or obese dogs lost weight, whilst the remainder maintained normal weight. No clinically significant changes occurred within blood and urine. Blood levels of amino acids and vitamins were all generally maintained.

In a few cases, previous deficiencies following a meat-based diet either improved or disappeared, including L-taurine and L-carnitine (important for cardiac health), vitamin D (indispensable for immunity and bone health), and folate (required to produce red blood cells).

The study was particularly interesting, given recent suggestions that peas might contribute to heart disease in dogs in the US. Although no credible evidence has been found, such concerns have persisted in some quarters. In the current study, dogs were fed pea-based vegan pet food, for one year. Blood markers of cardiac health were assessed, with no signs of heart disease found. Indeed, in some cases indicators of cardiac health improved.

Stated lead researcher, veterinarian Dr. Annika Linde from the Western University of Health Sciences near Los Angeles says, "Evolutionary adaptations have resulted in a digestive system that enables dogs to maintain health on nutritionally complete omnivorous diets, including those free of animal ingredients. Our study offers new evidence on outcomes in clinically healthy dogs who thrive without consumption of animal-derived ingredients. Notably, foods produced independent of factory farming are also more sustainable and ethical."

Study co-author Dr. Melgarejo highlighted the potential environmental benefits of such diets, "If dogs and cats in the U.S. were their own nation, they would rank fifth in global meat consumption, surpassed only by Russia, Brazil, USA, and China, according to the UCLA Institute of the Environment and Sustainability."

Veterinary Professor Andrew Knight has published several of the key studies in this field, including very large-scale studies showing that both dogs and cats normally achieve equivalent or superior health outcomes, when fed nutritionally-sound vegan diets. He also analysed the environmental benefits of vegan pet diets in a major recent study. He stated that "If all the world's dogs went vegan, it would save more greenhouse gases than those emitted by the UK, land larger than Mexico, and 450 million additional people could be fed with food energy savings - more than the entire EU population. With 13 studies now demonstrating good health outcomes achieved by nutritionally-sound vegan pet diets, and several others demonstrating major environmental benefits, a compelling case now exists for environmentally-friendly vegan pet diets."

Contact Information:

Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@winchester.ac.uk

SOURCE: Representing Animals Foundation

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESSWIRE

DK

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release

During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h

Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release

WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release

TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on

Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release

IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye